VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LABStandard BioTools Inc.
$0.54$211M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLABBalance Sheet

Standard BioTools Inc. (LAB) Balance Sheet

20Y historyFree accessUpdated daily

Leverage is low with debt-to-equity at 0.05 and cash of $267.5M against $79.6M of total liabilities, though the shrinking asset base and deeply negative retained earnings suggest investors should monitor dilution exposure.

Income StatementBalance SheetCash FlowRatios

LAB Balance Sheet

Annual statement

LAB Balance Sheet

Standard BioTools Inc. (LAB) balance sheet — 20-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06
Total Current Assets497.3M454.26M375.88M158.22M208.81M72.07M117.66M96.1M127.11M94.8M96.67M144.09M155.9M104.58M101.21M70.03M20.88M28.48M29.23M50.33M31.09M
Cash & Short-Term Investments461.11M187.57M292.87M114.89M165.78M28.45M68.52M58.64M95.4M63.14M59.43M94.97M115.3M84.34M80.01M53.47M5.72M14.6M17.8M40.36M25.52M
Cash Only267.49M118.21M166.73M51.7M81.31M28.45M68.52M21.66M95.4M58.06M35.05M29.12M33.71M35.26M58.65M13.55M5.72M14.6M17.8M34.08M25.02M
Short-Term Investments193.62M69.36M126.15M63.19M84.47M0036.98M05.08M24.39M65.86M81.59M49.08M21.36M39.91M0006.29M500K
Accounts Receivable12.98M13.43M33.61M19.66M17.28M18.32M25.42M18.98M16.65M15.05M14.61M25.46M22.38M10.55M12.9M9.25M8.1M8.69M4.71M1.9M1.76M
Days Sales Outstanding63.5557.4570.3267.4864.3951.2167.1759.0953.853.8951.068170.1654.1189.9778.7988.1124.82111.9295.33100.69
Inventory17.62M19.98M40.74M20.53M21.47M20.82M19.69M13.88M13M15.09M20.11M17.92M15.99M8.15M7.17M5.97M4.89M3.94M5.46M5.5M3.04M
Days Inventory Outstanding161.09170.45164.9134.09128.7124.19131.195.6892.49110.24159.57140.3136.22148.1170.75165.19154.21125.36238.1571.08399.88
Other Current Assets5.59M233.28M8.66M3.13M4.28M16K002.05M1.53M2.52M001.54M01.34M2.17M00500K0
Total Non-Current Assets138.03M113.49M236.46M164.85M181.5M203.15M207.09M168.72M176.54M192.55M209.72M226.97M251.66M12.33M12.52M9.29M3.92M3.67M3.13M4.45M5.4M
Property, Plant & Equipment36.32M46.01M71.38M54.85M59.53M65.15M55.65M12.92M8.82M12.3M16.52M15.26M13.89M6.82M4.97M3.26M2.33M1.93M2.78M3.38M4.07M
Fixed Asset Turnover2.05x1.85x2.44x1.94x1.65x2.00x2.48x9.08x12.80x8.29x6.32x7.52x8.38x10.44x10.52x13.16x14.42x13.17x5.53x2.15x1.57x
Goodwill00111.3M106.32M106.25M106.38M106.56M104.11M104.11M104.11M104.11M104.11M104.11M00000000
Intangible Assets0028.95M1.4M12.6M27.93M42.22M49.13M57.4M68.6M79.8M91.05M102.2M1.24M0000000
Long-Term Investments262.58M25.7M0001M000006.49M27.5M1.94M3.67M2.84M1.34M0000
Other Non-Current Assets3.19M3.15M24.83M2.29M3.11M3.69M2.66M2.56M6.21M7.54M9.29M10.06M3.97M3.57M3.88M3.2M252K1.74M352K1.07M1.34M
Total Assets635.33M567.75M612.34M323.07M390.31M275.21M324.76M264.81M303.65M287.35M306.39M371.06M407.56M116.92M113.73M79.33M24.8M32.15M32.35M54.78M36.49M
Asset Turnover0.14x0.15x0.28x0.33x0.25x0.47x0.43x0.44x0.37x0.35x0.34x0.31x0.29x0.61x0.46x0.54x1.35x0.79x0.47x0.13x0.18x
Asset Growth %33.33%-7.28%89.54%-17.23%41.82%-15.26%22.64%-12.79%5.67%-6.22%-17.43%-8.96%248.59%2.8%43.37%219.85%-22.87%-0.62%-40.93%50.1%-
Total Current Liabilities51.02M108.31M65.89M109.33M43.44M49.57M54.25M32.82M37.58M33.47M29.5M30.08M29.39M17.25M11.6M20.17M18.51M7.13M8.52M11.57M7.15M
Accounts Payable3.45M5.41M12.28M9.24M7.91M10.6M9.22M5.15M4.03M4.21M3.97M6.09M5.92M4.35M2.56M4.01M3.15M2.22M2.86M2.73M1.19M
Days Payables Outstanding58.0746.1249.7260.3247.4363.2261.3935.528.6430.7731.4747.750.4279.1260.85110.9699.4470.67124.81283.05156.37
Short-Term Debt5.69M5.49M059.53M2.08M6.84M0000000008.92M7.69M01.03M3.83M3.48M
Deferred Revenue (Current)73.62M38.95M18.59M16.73M14.44M15.48M16.39M11.8M11.46M10.24M9.16M9.42M6.93M2.72M1.89M2.01M1.34M758K1.41M2.65M1.01M
Other Current Liabilities28.8M58.46M14.71M12.05M3.96M8.67M11.21M3.84M7.62M10.54M12.37M3.55M6.87M5.39M2.88M2.79M1.05M616K141K468K223K
Current Ratio9.75x4.19x5.70x1.45x4.81x1.45x2.17x2.93x3.38x2.83x3.28x4.79x5.31x6.06x8.73x3.47x1.13x4.00x3.43x4.35x4.35x
Quick Ratio9.40x4.01x5.09x1.26x4.31x1.03x1.81x2.50x3.04x2.38x2.60x4.19x4.76x5.59x8.11x3.18x0.86x3.44x2.79x3.87x3.92x
Cash Conversion Cycle166.57181.77185.51141.26145.66112.17136.88119.27117.65133.36179.15173.6155.95123.09199.86133.02142.87179.51225.21383.36344.2
Total Non-Current Liabilities28.56M35.15M74.73M361.79M428.33M131.05M131.46M78.38M193.95M222.94M223.66M226.08M227.75M2.55M1.48M2.26M195.46M198.64M182.17M173.53M135.51M
Long-Term Debt300K299K299K3.98M62.81M64.21M54.22M53.82M172.06M195.24M194.95M195.68M195.46M001.22M10.14M14.46M14.18M10.53M22.43M
Capital Lease Obligations91.7M25.04M26.47M30.37M34.08M37.55M38.18M4.32M00000000-184.55M0000
Deferred Tax Liabilities3.28M810K1.08M841K1.05M4.33M8.7M11.49M13.71M16.92M21.14M23.59M26.15M000184.55M183.84M167.54M162.08M-17.55M
Other Non-Current Liabilities1.12M1.21M6.96M312.32M312.21M882K1.33M573K1.85M5.83M3.26M2.4M1.79M651K237K374K-184.21M79K144K163K112.3M
Total Liabilities79.58M143.46M140.62M471.12M471.78M180.62M185.71M111.2M231.53M256.42M253.16M256.16M257.14M19.8M13.07M22.43M213.97M205.77M190.69M185.11M142.66M
Total Debt26.83M30.83M33M98.21M102.66M111.65M95.38M59.98M172.06M195.24M194.95M195.68M195.46M0010.14M17.82M14.46M15.21M14.36M25.91M
Net Debt-240.65M-87.39M-133.73M46.51M21.35M83.2M26.86M38.32M76.66M137.18M159.91M166.57M161.74M-35.26M-58.65M-3.42M12.1M-141K-2.58M-19.72M892K
Debt / Equity0.05x0.07x0.07x--1.18x0.69x0.39x2.39x6.31x3.66x1.70x1.30x--0.18x-----
Debt / EBITDA-0.38x--------------------
Net Debt / EBITDA3.37x--------------------
Interest Coverage-16186.40x-3718.31x-40.71x-15.25x-43.55x-15.65x-14.15x-14.59x-3.42x-9.95x-12.78x-8.43x-9.80x-1169.64x-29.08x-6.19x-6.79x-5.67x-13.60x-8.08x-9.42x
Total Equity555.75M424.29M471.72M-148.05M-81.47M94.6M139.05M153.61M72.12M30.93M53.23M114.9M150.42M97.12M100.66M56.9M-189.17M-173.62M-158.34M-130.33M-106.17M
Equity Growth %79.63%-10.05%418.62%-81.73%-186.12%-31.97%-9.48%113.01%133.12%-41.89%-53.67%-23.61%54.88%-3.52%76.91%130.08%-8.96%-9.65%-21.49%-22.75%-
Book Value per Share1.411.111.34-1.87-1.041.251.932.301.820.941.844.005.423.814.553.19-9.97-100.01-95.79-68.96-56.18
Total Shareholders' Equity555.75M424.29M471.72M-148.05M-81.47M94.6M139.05M153.61M72.12M30.93M53.23M114.9M150.42M97.12M100.66M56.9M-189.17M-173.62M-158.34M-130.33M-106.17M
Common Stock413K404K396K83K80K77K75K70K49K39K29K29K28K26K25K20K2K2K2K10K9K
Retained Earnings-1.15B-1.26B-1.19B-1B-926.1M-736M-676.76M-623.64M-558.85M-500.2M-439.48M-363.49M-310.18M-257.35M-240.82M-221.8M-199.33M-182.43M-163.3M-133.8M-108.27M
Treasury Stock-46.47M-46.47M-46.47M-5.98M-563K0000000000000000
Accumulated OCI354K-1.49M1.23M-2.22M-1.9M-907K112K-582K-687K-574K-760K-1.14M-794K-730K-769K-754K-778K-504K-556K-135K-17K
Minority Interest000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Persistent operating burn and deficit

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Shrinking Asset Base Masks Deleveraging

According to reported quarterly figures, LAB total assets declined from $708.7M in 2024Q2 to $635.3M in 2026Q3, a contraction of roughly 10%, while total liabilities fell from $198.5M to $79.6M, suggesting the balance sheet is contracting rather than growing.

Much of the liability reduction reflects debt repayment from roughly $90M to under $30M and a sharp drop in deferred revenue, which suggests obligations were retired rather than refinanced. The goodwill balance falling from $111M to zero points to impairment-driven shrinkage, meaning part of the asset decline is non-cash and does not reflect operating reinvestment. Investors should monitor whether the smaller asset base can support revenue stabilization without further write-downs.

Debt Reduced to Minimal Leverage

As reported in the balance sheets, LAB total debt dropped from $90.5M in 2024Q2 to $26.8M in 2026Q3, lowering debt-to-equity from 0.18 to 0.05 and leaving leverage low relative to equity.

The steep decline appears to reflect repayment rather than a shift toward cheaper financing, and the reported figures do not disclose the terms or maturity profile of the remaining obligations. With D/E at 0.05, leverage is unlikely to be the binding constraint, so the analytical focus shifts to whether operating cash generation can service the business without relying on the balance sheet. Further review of the debt schedule would be warranted before drawing firm conclusions about refinancing risk.

Cash Buffer Solid but Burn Erodes It

Based on LAB's reported balance sheets, cash stood at $267.5M in 2026Q3 against a current ratio of 9.75, a liquidity position that appears substantial relative to $79.6M of total liabilities.

The high current ratio is partly a function of a small current liabilities base, so cash runway against continuing operating losses is the more meaningful measure. Cash moved from $270.0M in 2026Q2 to $267.5M in 2026Q3, but fell sharply from roughly $265M in 2026Q1 to $118M in 2025Q4, a movement that warrants investigation given the reported figures. The buffer looks adequate in the near term, but its trajectory depends on whether operating burn persists at recent levels.

Asset Base Shifting Away From Plant

Based on reported figures, LAB's net PP&E fell from $74.1M in 2024Q2 to $36.3M in 2026Q3, suggesting the asset base is becoming less capital-intensive as cash and receivables take a larger share of total assets.

The PP&E decline alongside the disappearance of reported goodwill points to a balance sheet increasingly weighted toward liquid and working-capital assets rather than long-lived operating assets. This profile is consistent with an asset-light position, though it may also reflect reduced manufacturing capacity relative to the prior period. The reported data does not identify the drivers of the PP&E reduction, so the operational implications remain open for further review.

Headline Cash Masks Thin Recurring Base

As reported in the balance sheets, LAB's $267.5M cash balance and 9.75 current ratio look strong, yet retained earnings near -$1.1B suggest equity is sustained by paid-in capital rather than earned profits, which may understate dilution exposure.

A large cash position funded largely by external capital can look like a fortress while masking a history of cumulative losses that has not been reversed by operations. The reported data does not break out stock-based compensation or share issuance, so the extent of ongoing dilution cannot be fully assessed from the balance sheet alone. Investors should monitor future share issuance and cash burn against the accumulated deficit to judge whether the liquidity cushion is durable.

LAB — Frequently Asked Questions

Quick answers to the most common questions about buying LAB stock.

What are the total assets of Standard BioTools Inc. (LAB)?

As of 2025, Standard BioTools Inc. (LAB) had total assets of $567.8M including $454.3M in current assets.

How much debt does Standard BioTools Inc. (LAB) have?

Standard BioTools Inc. (LAB) carries total debt of $30.8M, offset by $187.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Standard BioTools Inc.?

Standard BioTools Inc. (LAB) has total shareholders' equity (book value) of $424.3M ($1.11 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Standard BioTools Inc.'s current ratio and liquidity?

Standard BioTools Inc. (LAB) reported a current ratio of 4.19x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.